McGlone Suttner Wealth Management Inc. Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

McGlone Suttner Wealth Management Inc. grew its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 74.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,871 shares of the company's stock after buying an additional 4,218 shares during the period. McGlone Suttner Wealth Management Inc.'s holdings in Johnson & Johnson were worth $1,637,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Compass Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 14.3% in the first quarter. Compass Wealth Management LLC now owns 3,682 shares of the company's stock valued at $611,000 after purchasing an additional 460 shares during the last quarter. Viewpoint Capital Management LLC lifted its holdings in Johnson & Johnson by 2.7% during the first quarter. Viewpoint Capital Management LLC now owns 14,436 shares of the company's stock valued at $2,394,000 after purchasing an additional 385 shares during the last quarter. Sierra Ocean LLC lifted its holdings in Johnson & Johnson by 10.9% during the first quarter. Sierra Ocean LLC now owns 2,264 shares of the company's stock valued at $376,000 after purchasing an additional 222 shares during the last quarter. Bolthouse Investments LLC purchased a new stake in Johnson & Johnson during the first quarter valued at about $234,000. Finally, Concurrent Investment Advisors LLC lifted its holdings in Johnson & Johnson by 20.2% during the first quarter. Concurrent Investment Advisors LLC now owns 112,427 shares of the company's stock valued at $18,645,000 after purchasing an additional 18,902 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded down $0.82 during mid-day trading on Friday, reaching $156.87. 7,866,488 shares of the company traded hands, compared to its average volume of 8,066,975. The firm has a market cap of $377.44 billion, a PE ratio of 17.45, a PEG ratio of 2.15 and a beta of 0.41. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company's 50 day moving average price is $153.73 and its 200-day moving average price is $154.35. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on JNJ shares. Raymond James Financial reduced their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research note on Monday, April 14th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Finally, Bank of America dropped their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $171.00.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.